• Genprex received patent grant from Israel Patent Office covering use of Reqorsa gene therapy with PD-1 antibodies to treat cancer.
• Grant expands Genprex intellectual property protection for this combination in Israel, adding to patents already issued in major markets.
• Reqorsa is being developed in combination regimens for lung cancer, with clinical programs in NSCLC and SCLC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604300800PR_NEWS_USPR_____DA47167) on April 30, 2026, and is solely responsible for the information contained therein.